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Abstract
Background—In the United States, women, racial/ethnic minorities and persons who acquire
HIV infection through heterosexual intercourse represent an increasing proportion of HIV infected
persons, yet are frequently underrepresented in clinical trials. We assessed the demographic
predictors of trial participation in antiretroviral naïve patients.
Methods—Patients were characterized as trial participants if highly-active antiretroviral therapy
(HAART) was initiated within a clinical trial. Prevalence ratios (PR) were obtained using
binomial regression.
Results—Between 1996–2006, 30% of 738 treatment naïve patients initiated HAART in a
clinical trial. Trial participation rates for MSM, heterosexual men, and women were respectively
36.5%, 29.6% and 24.3%. After adjustment for other factors, heterosexual men appeared less
likely to participate in trials compared to MSM (PR: 0.79, 95%CI 0.57, 1.11) while women were
as likely to participate as MSM (PR 0.97, 95%CI 0.68, 1.39). The participation rate in blacks
(25.9%) was lower compared to non-blacks (37.5%) (adjusted PR 0.80, 95%CI 0.60, 1.06).
Conclusions—In our clinical setting gender did not appear to impact participation in HIV
treatment trials but blacks were slightly less likely to participate in these trials. Considering the
substantial proportion of HIV patients who are black, future trials need to consider strategies to
incorporate underrepresented populations.
Keywords
HIV infection; clinical trials; highly active antiretroviral therapy; gender; sexual orientation; race
Introduction
Well designed randomized clinical trials remain the principal source of reliable evidence
about treatment efficacy. Persons living with HIV infection are a diverse and heterogeneous
population and the ability to generalize the results of HIV treatment trials is directly related
to how well participants in these trials represent the larger HIV-infected population.
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Treatment guidelines are based on treatment trials data but participants in these trials may
not reflect the overall HIV infected community1, 2.
In the decade since the introduction of highly active antiretroviral therapy (HAART), the
demographics of the HIV/AIDS epidemic in the United States (US) has changed. In 2006
blacks made up 13% of the US population but accounted for 49% of reported AIDS cases
and currently women account for more than one quarter of all new HIV diagnoses3. High
risk heterosexual contact has emerged as a major route of transmission representing 80% of
all new HIV diagnosis in women3. Despite these notable increases in the rates of infection
among blacks, women and heterosexuals these groups are reportedly underrepresented in
HIV treatment trials4, 5.
Most studies evaluating participation in HIV/AIDS clinical trials are limited as they were
conducted very early in the HIV epidemic, prior to the widespread use of HAART and are
therefore unable to address these demographic changes6–11. Furthermore, these studies had
conflicting results with some studies reporting women were not underrepresented in clinical
trials, others disagreeing, and still others unable to address this issue7–9, 11. Although, there
appears to be greater consensus that non white persons are less likely to participate in
clinical trials this was not found to be the case in all studies6–11. A recent study observed
that women were more likely than men to participate in HIV treatment trials only when
stratifying by risk for HIV transmission thus excluding MSM a high proportion of the study
population12. Answering specific questions in HIV infected women and underrepresented
minorities may require trials that actually enrich for participation of these groups.
Nonetheless, given the changes in the face of the epidemic and the contradictory nature of
earlier results, an updated assessment of trial participation is needed to inform clinicians,
researchers and policy makers about the generalizability of treatment trial data and whether
enrollment into such trials achieves the goals for the inclusion of women and minorities in
clinical trials established in National Institutes of Health (NIH) and Food and Drug
Administration guidelines13–15.
The University of North Carolina (UNC) Center for AIDS Research (CFAR) HIV/AIDS
clinical cohort (UCHCC) comprises over 2000 HIV-positive trial and non-trial patients and
is one of the largest ongoing clinical cohorts in the southeast US. Since its inception, the
UCHCC has captured the changing demographics of the HIV epidemic with over one third
of the cohort being women and close to two thirds African American. The UCHCC provided




We conducted a cross sectional study of baseline demographic and behavioral, access to
care, and clinical characteristics for trial and non-trial participants using the UNC CFAR
HIV/AIDS Clinical Cohort. This cohort comprising HIV positive persons (≥ 18 years) who
receive health care at the UNC Hospital Infectious Disease (ID) clinic has been described
previously16, 17. Over 95% of the UNC ID clinic population has consented to participate in
the UCHCC. Patients who decline participation in the UCHCC do not differ significantly
from those who participate. This study was approved by the Biomedical Institutional Review
Board of the University of North Carolina at Chapel Hill
Study population
For this analysis the study population comprised antiretroviral treatment naïve HIV-positive
subjects who received care in the UNC ID clinic between the years 1996 – 2006, and
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initiated HAART defined as any combination of three or more antiretroviral agents or at
least one protease inhibitor and one non-nucleoside reverse transcriptase inhibitor. Subjects
were characterized as trial participants if HAART was initiated as part of a treatment trial.
Treatment trials included NIH AIDS Clinical Trial Group (ACTG) supported or industry
sponsored trials and may or may not have been randomized, placebo controlled or blinded.
Variable Specification
Gender (male/female) and sexual orientation (heterosexual/homosexual/bisexual) were
primary and mutually exclusive exposure variables. Men who have sex with men (MSM)
and bisexual men were placed in one category. However, because there were no homosexual
females and MSM is a subset of all men we specified a joint gender and sexual orientation
variable with three categories (females/heterosexual males/MSM) to clarify interpretation of
coefficients in the multivariable regression. Race/ethnicity was categorized as black or non
black and this category included White, Hispanic, Native American and other races. Race/
ethnicity and sexual orientation were self reported and based on subject’s characterization of
personal self-identity.
Additional variables included Centers for Disease Control and Prevention (CDC)
categorization of AIDS18 (excludes subjects with a CD4 <200 cells/uL if they had no other
AIDS defining illness) insurance status (Medicaid/Medicare, none and private/other),
distance traveled from home to the ID clinic, injection drug use (IDU) as a risk for HIV
acquisition and time from HIV diagnosis to HAART initiation. IDU was self reported, while
date of HIV diagnosis was based on either self report or testing. These variables were
evaluated at baseline, which was defined as the date of HAART initiation, except for AIDS
diagnosis, which was evaluated at any time before and up to 14 days after the date of
HAART initiation.
Selected laboratory values that may influence initiation of HAART were analyzed including
CD4 cell count, plasma HIV RNA level, hemoglobin, creatinine, alanine aminotransferase
[ALT], and absolute neutrophil count [ANC]. However, as laboratory results may not be
available on the same day HAART was initiated an extended baseline period was
considered, with baseline values being defined as those closest to the day of HAART
initiation within a window spanning 180 days before and up to 14 days after the date
HAART was started. For ALT, ANC, creatinine and hemoglobin, gender appropriate normal
ranges were accounted for and these variables’ values were categorized as normal or
abnormal.
Statistical Analyses
Descriptive statistics (proportions, mean, median, range, standard deviation) were generated
for all variables considered in the analysis. Visual summaries were used to assess if
continuous variables were normally distributed. Variables that deviated substantially from
normality were transformed (e.g. HIV RNA levels were transformed to the log base 10
scale) to arrive at an approximately normal distribution. Linearity was assessed using a
quadratic spline model and a likelihood ratio test comparing a model that included only the
variable to the model with the restricted splines. This preliminary analysis and substantive
knowledge informed decisions about creation of category boundaries or whether to retain
continuous variables in linear models.
Predictors of trial participation were contrasted by trial participation status using the Pearson
χ2 test for categorical variables, the Wilcoxon sum rank test for non-normally distributed
continuous variables, or the Student’s t test for normally distributed continuous variables.
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Gender/sexual orientation and race/ethnicity were considered as the two predictors of
interest for this analysis. Additional sub-group analysis was not conducted due to small
sample sizes. All other variables listed under variable specification were considered as
possible confounding factors and included in the full model.
To estimate adjusted prevalence ratios, we fit binomial models each with a poisson
distribution and robust variance estimator19–22. Note that the poisson distribution was used
to allow for convergence of the multivariate binomial models22. Interaction between each
primary predictor and each covariate was assessed with a likelihood ratio test (LRT) of a
product interaction term. A LRT p-value < 0.1 was considered evidence of interaction..
Missingness
A complete case analysis was first conducted excluding all observations with missing data.
We then assessed missingness by the three mechanisms identified by Little and Rubin23 i.e.
missing completely at random, missing at random (MAR), and not missing at random. We
determined in this data set missingness may be categorized as MAR, as the probability of
the missing value is likely independent of the value itself but dependent on the values of
other variables in the data set. We assessed the potential effect of missing data on our effect
estimates, by using a multiple imputation method with five imputed data sets23–25. Similar
to the complete case analysis, a binomial regression model with a poisson distribution and a
robust error variance was run on the imputed data sets.
Intercooled Stata (version 9.0), Stata Corporation, (College Station, TX) was used for all
analyses. The multiple imputation was conducted using Stata’s ICE program26.
Results
Population Characteristics
Between1996–2006, 738 treatment naïve persons initiated HAART. One-third (n=224) of
patients initiated and received HAART by participating in 13 different HIV treatment trials.
Nine trials were sponsored by the ACTG and four by pharmaceutical companies (Table 1).
The mean age of patients was 38.5 years (sd 9.0), 31% were women, 62% were Black, 28%
were White, 6.8% were Hispanic and almost 2% were Native American (Table 2). Greater
than a third (37.4%) of subjects had no insurance; one quarter (25.6%) had public insurance
(Medicaid and/or Medicare). At baseline, 26% of subjects had an AIDS diagnosis, the
median CD4 cell count was 157 cells/uL (IQR 40-345) and the mean viral load was 4.7
log10 (sd 1.0). One-half of subjects initiated HAART within 5 months of receiving a
diagnosis of HIV. The median distance traveled one way to receive care at the UNC ID
clinic was 47 miles (IQR 27-71). The major risk factor for HIV acquisition was heterosexual
intercourse (54.1%) with only 13% of subjects reporting IDU as a risk factor.
Gender/Sexual Orientation and Trial Participation
Trial participation rates for MSM, heterosexual men, and women were respectively 36.5%,
29.6% and 24.3% and these rates differed significantly (p=0.02). In bivariable analysis
compared to MSM, heterosexual men (PR 0.81 95%CI 0.63, 1.04) and women (PR 0.67
95%CI 0.50, 0.88) were less likely to enroll in HIV treatment trials. After adjustment
heterosexual men were slightly less likely (PR 0.79, 95% CI 0.57, 1.11) and women were no
less likely (PR 0.97, 95%CI 0.68, 1.39) to enter these trials than MSM (Table 3).
To evaluate which variables were responsible for the substantial change in the adjusted
prevalence ratio comparing women to MSM, we eliminated variables one at a time from the
multivariable model and found that insurance status and months from HIV diagnosis to
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HAART initiation accounted for most of the change. Without adjusting for months from
HIV diagnosis to HAART initiation women were 14% less likely to participate in trials (PR
0.86 95% CI 0.62, 1.18). Similarly without adjusting for insurance status women were 15%
less likely to participate in these trials (PR 0.85 95% CI 0.60, 1.19).
Race/ethnicity and Trial Participation
Trial participants differed significantly from non trial participants by race/ethnicity
(p=0.001). Although blacks comprised the greater proportion (62%) of patients only 26% of
them enrolled in treatment trials. In bivariable analysis blacks compared to non-blacks were
significantly less likely to participate in treatment trials (PR 0.69, 95%CI 0.56, 0.86). After
adjustment, blacks remained slightly less likely to participate in treatment trials than non
blacks (PR 0.80, 95% CI 0.60, 1.06) (Table 3).
Imputed data
The imputed data sets produced adjusted prevalence ratio estimates that were generally
similar to the results obtained in the complete case analysis (Table 3). The point estimate for
heterosexual men was closer to the null after imputation (PR 0.90; 95% CI 0.70, 1.16), while
the point estimate for women was slightly further from the null, although the confidence
interval included the null (PR 0.91; 95% CI 0.68, 1.22). The point estimate for blacks was
virtually unchanged (PR 0.78, 95% CI 0.62, 097). Overall, the confidence interval estimates
of the imputed prevalence ratios were narrower than those obtained in the complete case
analysis.
Discussion
We observed a high rate of participation in HIV treatment trials in this cohort. In
multivariable analysis compared to MSM, heterosexual men were less likely while women
were as likely to participate in HIV treatment trials. Blacks were slightly less likely to
participate in these trials when compared to non-blacks.
Almost one-third of treatment naïve persons received HAART through participating in a
treatment trial. Previous studies using the HIV cost and services utilization data and the
HIV/AIDS surveillance project data reported lower participation rates of 14% and 17%
respectively7, 12. Participation in HIV research is reportedly influenced by concern about
receiving placebo, lack of information about research, and travel or transport obstacles27.. In
terms of lack of information we have a dedicated research screener in the ID clinic whose
role is to provide information about clinical trials to patients and a social worker who assists
with transportation issues. All the clinical trials included in this analysis involved active
antiretrovirals; placebos were only used for the purpose of blinding in combination with
active treatments. Our success in recruiting patients into clinical trials may partly be related
to the ability of our research site to address these factors and other sites wishing to increase
trial participation might consider and address similar factors.
In our cohort women were less likely than MSM to participate in clinical trials. However,
after adjusting for other factors we found no difference in participation rates between
women and MSM a finding supported by other studies 7, 9, 12. We found that women’s
participation in clinical trials was particularly influenced by insurance status and months
from HIV diagnosis to HAART initiation. Although having no or sub-optimal health
insurance may influence trial participation there are multiple other reasons for trial
participation as evidenced by the fact that a significant proportion of subjects with health
insurance participated in these trials. More women had health insurance (public or private)
than men and almost one half of all women had public insurance (Medicaid and/or
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Medicare). While not a program restricted to women, over two thirds of adults (≥18 years)
on Medicaid are women28, 29. Furthermore, one study reported that in North Carolina
women comprised 47% of all HIV infected Medicaid beneficiaries30. Having health
insurance likely provides women with access to treatment, care and other health benefits and
may limit their need to participate in clinical trials. Insurance status could also be a marker
for unmeasured variables, such as socio-economic stability or education level, which could
potentially influence decisions about trial participation.
Several reasons might explain why months from HIV diagnosis to treatment appeared to
influence women’s participation in trials. In general, untreated HIV infected women have an
approximately 0.2 log lower viral load than men31. This difference was also observed in our
cohort. As our study encompasses 1996–2006 during which the US Department of Health
and Human Services guidelines indicated that both CD4 cell count and HIV RNA should be
used to guide therapy decisions especially for asymptomatic persons this may have been
partly responsible for delay in women initiating HAART. Reportedly, women may also
delay entry into care by more than three months after receiving an HIV diagnosis32.
Therefore, we suspect that the combination of two effects - 1) a delay in receipt of HAART
appeared to increase participation and 2) women were more likely to delay receipt of
HAART - were at least partly responsible for our results.
We sought to distinguish the effect of gender from that of sexual orientation on trial
participation. Previous studies included gender and sexual orientation (or risk group) in the
same model and thus could not achieve this distinction 6, 7, 9. Compared with MSM
participation rates for heterosexual men though slightly lower were not significantly
different. Prior reports of lower representations by heterosexuals may have simply been a
reflection that this group included mostly women. Our results suggest that, in our setting,
both gender and sexual orientation do not significantly influence participation in HIV
treatment trials.
Although, blacks appeared less likely than non blacks to participate in trials, the strength of
this association diminished when accounting for other variables and the absolute difference
(8%) was even smaller (data not shown). These results are similar to other HIV related
studies suggesting blacks were less likely than either Caucasians or other ethnicities to enter
clinical trials6–8, 11. It is however noteworthy that the difference observed was not
substantial and could partially be explained by adjustment for other variables. Possibly
additional adjustment for unmeasured variables, might have further diminished this observed
difference. Historically blacks have been less likely to participate in clinical trials due to
distrust in medical research, lack of confidence in providers and to the belief that the
informed consent process provides patients with little protection33, 34.
We feel that our results reflect a trend supporting decrease in disparities for black enrolment
into trials. The UNC ID clinic has a high proportion of black patients but there are likely
other reasons why the difference we observed was small including lack of clinician bias in
referral and enrolment of patients into trials and strong patient provider trust. A major
barrier to blacks participating in HIV treatment trials is not being asked to participate and in
fact a systematic review of health research studies showed that when invited to participate
blacks were as likely and sometimes more likely to participate in research1, 35. Provider
endorsement of trials, provision of clinical trial information by providers and trust in
providers is associated with trial participation7, 36–38.
We did not examine trends in participation over time and changes in demographics by
calendar year. Our results were likely less influenced by demographic changes in trial
participation over time but instead may reflect the availability or lack thereof of a treatment
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naïve trial and the type of therapy being offered in the trial. Unfortunately, we do not have
precise data on the availability of a clinical trial when a treatment naïve person eligible for
ART presented for care. We would like to note that other studies that have looked at
participation in clinical trials have likely been unable to address this issue and have therefore
broadly categorized participation as self reported participation in any medication trial or
study7,12. We submit that our study has additional merit as we were able to refine our study
by 1) only identifying persons who enrolled in treatment naive studies and 2) independently
confirming participation without reliance on self report. As with study availability, clinician
influence both positive and negative is likely to impact any study of this type. Literacy and
education level are potential barriers to trial participation. To address this we ensure that all
consent forms are written at a 6th–8th grade level of understanding. Moreover, if literacy is
noted as a problem, there is a provision in all our studies to have the entire informed consent
read to the subject.
Since our data represent a single clinic population, these results may not be generalizable to
other settings or parts of the country. However, as the UCHCC comprises about 10% of all
HIV infected individuals in NC, it is probably representative of the HIV population in NC.
Moreover, six southeastern states (North Carolina, South Carolina, Mississippi, Alabama,
Georgia, Louisiana) report demographically similar epidemics supporting the
generalizability of these results to the southeast US39–41. The comparable rates of enrolment
between blacks and non blacks and between genders and those of different sexual
orientations may partly be attributed to the demographic make up of the ID clinic and to the
existing ACTG. Previous studies have shown that, compared to other ACTG sites, the UNC
ACTG has high trial enrolment rates for racial/ethnic minorities and for women trial
participation is associated with living in an area with a NIH or CDC supported research
network12, 34. In addition, NC has historically had strict eligibility criteria for the state
funded AIDS Drug Assistance Program (ADAP). Limited access to ADAP may leave
participation in HIV treatment trials as the only option for access to antiretroviral therapy.
Finally, we recognize that several unmeasured variables including work pressures, child
bearing wishes and vertical transmission issues could have influenced our study results.
In summary, in the clinical setting studied we achieved high rates of participation in HIV
treatment trials. Gender did not appear to impact participation in HIV treatment trials but
blacks were slightly less likely to participate in these trials. We hypothesize, that in part our
results might be explained by guidelines and policies adopted both in the US and other
countries to correct imbalance in trial participation15, 42. Considering the substantial
proportion of HIV-patients who are black, future trials need to consider strategies to further
incorporate underrepresented populations. Further investigation into the role of insurance in
trial participation is needed. A continued exploration of barriers to clinical trial participation
must consider other factors including trust issues, awareness and information about clinical
trials and trial characteristics.
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Table 1
Description of Clinical Trials included in the study
Study N Percent Study Treatments




ZDV/3TC + EFV + NFV
ddI/d4T + EFV + NFV
ACTG 388 10 4.46 ZDV/3TC + IDV
ZDV/3TC + IDV + EFV
ZDV/3TC + IDV + NFV
A5015 6 2.68 d4T + FTC + LPV/RTV
A5073 6 2.68 FTC+TFV + LPV/RTV
FTC + d4T + LPV/RTV
A5095 51 22.77 ZDV/3TC/ABC
ZDV/3TC + EFV
ZDV/3TC/ABC + EFV
A5142 25 11.16 ZDV (or d4t XR) + 3TC + EFV
ZDV (or d4t XR) + 3TC + LPV/RTV
EFV + LPV/RTV
A5164 19 8.48 The study provided ARVs including LPV/r, d4T and TDF/FTC but clinicians were free to use any standard
ART.
A5175 8 3.57 ZDV/3TC + EFV
ddI/FTC + ATV
FTC/TFV + EFV




Abbott M97 9 4.02 d4T + 3TC+ LPV/RTV
Gilead 903 12 5.36 d4T + 3TC + EFV
TDF + 3TC + EFV
Gilead 934 1 0.45 FTC/TFV + EFV
ZDV/3TC + EFV
KLEAN 7 3.13 ABC/3TC + FPV/RTV
ABC/3TC + LPV/RTV
Total 224 100
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